Recombinant Human Erythropoietin After Bone Marrow Transplantation — A Placebo Controlled Trial
Several historically controlled studies [1,3,5] and one small open prospective randomized trial  showed an acceleration of erythropoietic recon-stitution after allogeneic bone marrow transplantation (BMT). Some authors claimed a stimulatory effect on thrombopoiesis after BMT [2,4]. This double-blind, placebo-controlled randomized trial was conceived to analyze the impact of rHu EPO on regeneration of erythro-poiesis after allogeneic or autologous bone marrow transplantation.
KeywordsPlacebo Leukemia Erythropoietin Erythro
Unable to display preview. Download preview PDF.
- 3.Mitus AJ, Antin JH, Rutherford CJ, et al. Significant reduction in homologous red cell transfusion requirements with the use of recombinant human erythropoietin in allogeneic bone marrow transplantation. Blood 1992, 80, (Suppl. 1) 330aGoogle Scholar
- 4.Stegmann JL, Lopez J, Otero JM, et al. Erythropoietin treatment in allogeneic BMT accelerates erythroid reconstitution: results of a prospective controlled randomized trial. Bone Marrow Transplant. 1992, 10: 541–546.Google Scholar